184 related articles for article (PubMed ID: 23652852)
1. Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration.
Donati OF; Lakhman Y; Sala E; Burger IA; Vargas HA; Goldman DA; Andikyan V; Park KJ; Chi DS; Hricak H
Eur Radiol; 2013 Oct; 23(10):2906-15. PubMed ID: 23652852
[TBL] [Abstract][Full Text] [Related]
2. The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration.
Burger IA; Vargas HA; Donati OF; Andikyan V; Sala E; Gonen M; Goldman DA; Chi DS; Schöder H; Hricak H
Gynecol Oncol; 2013 Jun; 129(3):586-592. PubMed ID: 23369941
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging/positron emission tomography provides a roadmap for surgical planning and serves as a predictive biomarker in patients with recurrent gynecological cancers undergoing pelvic exenteration.
Vargas HA; Burger IA; Donati OF; Andikyan V; Lakhman Y; Goldman DA; Schöder H; Chi DS; Sala E; Hricak H
Int J Gynecol Cancer; 2013 Oct; 23(8):1512-9. PubMed ID: 24257566
[TBL] [Abstract][Full Text] [Related]
4. Role of MR Imaging and FDG PET/CT in Selection and Follow-up of Patients Treated with Pelvic Exenteration for Gynecologic Malignancies.
Lakhman Y; Nougaret S; Miccò M; Scelzo C; Vargas HA; Sosa RE; Sutton EJ; Chi DS; Hricak H; Sala E
Radiographics; 2015; 35(4):1295-313. PubMed ID: 26172364
[TBL] [Abstract][Full Text] [Related]
5. Pelvic exenteration for primary and recurrent gynaecological malignancies.
de Wilt JH; van Leeuwen DH; Logmans A; Verhoef C; Kirkels WJ; Vermaas M; Ansink AC
Eur J Obstet Gynecol Reprod Biol; 2007 Oct; 134(2):243-8. PubMed ID: 16950559
[TBL] [Abstract][Full Text] [Related]
6. Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort.
Straubhar AM; Chi AJ; Zhou QC; Iasonos A; Filippova OT; Leitao MM; Awowole IO; Abu-Rustum NR; Broach VA; Jewell EL; Sandhu JS; Sonoda Y
Gynecol Oncol; 2021 Nov; 163(2):294-298. PubMed ID: 34518053
[TBL] [Abstract][Full Text] [Related]
7. The role of MR imaging in determining surgical eligibility for pelvic exenteration.
Popovich MJ; Hricak H; Sugimura K; Stern JL
AJR Am J Roentgenol; 1993 Mar; 160(3):525-31. PubMed ID: 8430546
[TBL] [Abstract][Full Text] [Related]
8. Pelvic Exenteration as Potential Cure and Symptom Relief in Advanced and Recurrent Gynaecological Cancer.
Soeda S; Furukawa S; Sato T; Ueda M; Kamo N; Endo Y; Kojima M; Nomura S; Kataoka M; Fujita S; Endo H; Takahashi T; Watanabe T; Yamada H; Fujimori K
Anticancer Res; 2019 Oct; 39(10):5631-5637. PubMed ID: 31570460
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in pelvic exenteration for gynecological malignancies.
Baiocchi G; Guimaraes GC; Rosa Oliveira RA; Kumagai LY; Faloppa CC; Aguiar S; Begnami MD; Soares FA; Lopes A
Eur J Surg Oncol; 2012 Oct; 38(10):948-54. PubMed ID: 22818842
[TBL] [Abstract][Full Text] [Related]
10. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers.
Fleisch MC; Pantke P; Beckmann MW; Schnuerch HG; Ackermann R; Grimm MO; Bender HG; Dall P
J Surg Oncol; 2007 May; 95(6):476-84. PubMed ID: 17192947
[TBL] [Abstract][Full Text] [Related]
11. Validation of MRI and Surgical Decision Making to Predict a Complete Resection in Pelvic Exenteration for Recurrent Rectal Cancer.
Brown WE; Koh CE; Badgery-Parker T; Solomon MJ
Dis Colon Rectum; 2017 Feb; 60(2):144-151. PubMed ID: 28059910
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of gynecologic oncology patients in King Chulalongkorn Memorial Hospital - complications and outcome of pelvic exenteration.
Oranratanaphan S; Termrungruanglert W; Sirisabya N
Asian Pac J Cancer Prev; 2013; 14(4):2529-32. PubMed ID: 23725169
[TBL] [Abstract][Full Text] [Related]
13. Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients.
Chiantera V; Rossi M; De Iaco P; Koehler C; Marnitz S; Ferrandina G; Legge F; Parazzini F; Scambia G; Schneider A; Vercellino GF
Int J Gynecol Cancer; 2014 Jun; 24(5):916-22. PubMed ID: 24442006
[TBL] [Abstract][Full Text] [Related]
14. Pelvic exenterations for gynecological malignancies: a study of 36 cases.
Kaur M; Joniau S; D'Hoore A; Van Calster B; Van Limbergen E; Leunen K; Penninckx F; Van Poppel H; Amant F; Vergote I
Int J Gynecol Cancer; 2012 Jun; 22(5):889-96. PubMed ID: 22617477
[TBL] [Abstract][Full Text] [Related]
15. Short- and long-term outcomes following pelvic exenteration for gynae-oncological and colorectal cancers: A 9 year consecutive single-centre cohort study.
Katory M; McLean R; Paez E; Kucukmetin A; Naik R
Int J Surg; 2017 Jul; 43():38-45. PubMed ID: 28529192
[TBL] [Abstract][Full Text] [Related]
16. Surgical salvage of recurrent rectal cancer after transanal excision.
Weiser MR; Landmann RG; Wong WD; Shia J; Guillem JG; Temple LK; Minsky BD; Cohen AM; Paty PB
Dis Colon Rectum; 2005 Jun; 48(6):1169-75. PubMed ID: 15793645
[TBL] [Abstract][Full Text] [Related]
17. Mesorectal lymph node involvement and prognostic implications at total pelvic exenteration for gynecologic malignancies.
Mourton SM; Chi DS; Sonoda Y; Alektiar KM; Venkatraman ES; Barakat RR; Abu-Rustum NR
Gynecol Oncol; 2006 Mar; 100(3):533-6. PubMed ID: 16226800
[TBL] [Abstract][Full Text] [Related]
18. Evolution of pelvic exenteration surgery- resectional trends and survival outcomes over three decades.
Waters PS; Peacock O; Warrier SK; Wakeman C; Eglinton T; Lynch AC; Frizelle FA; Heriot AG; McCormick J
Eur J Surg Oncol; 2019 Dec; 45(12):2325-2333. PubMed ID: 31303376
[TBL] [Abstract][Full Text] [Related]
19. Total pelvic exenteration for primary and recurrent malignancies.
Ferenschild FT; Vermaas M; Verhoef C; Ansink AC; Kirkels WJ; Eggermont AM; de Wilt JH
World J Surg; 2009 Jul; 33(7):1502-8. PubMed ID: 19421811
[TBL] [Abstract][Full Text] [Related]
20. Pelvic exenteration for recurrent or persistent gynecologic malignancies: a 10-year review of the Memorial Sloan-Kettering Cancer Center experience (1972-1981).
Lawhead RA; Clark DG; Smith DH; Pierce VK; Lewis JL
Gynecol Oncol; 1989 Jun; 33(3):279-82. PubMed ID: 2722049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
